CD8A and neoplasm: Additionally, three novel LAG-3 ligands have been reported: galectin-3, liver sinusoidal endothelial cell lectin (LSECtin), and fibrinogen-like protein 1 (FGL1) which are abundantly present in the tumor environment to help regulate and effectively abolish anti-tumor immunity of CD8+ T cells [6,7,8].